BioSpace News Archive

This funding will be used to support KaloCyte as it scales up in advance of human trials.

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it received notice from The Nasdaq Stock Market.

Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that the Company has entered into an Intellectual Property Licensing & Royalty Agreement (“IPLRA”) with Ei.Ventures, Inc. (“Ei.”) to develop and commercialize functional fungi-based products.

Indegene, a technology-led healthcare solutions provider, today announced that it joined The Metaverse Standards Forum to foster interoperability within healthcare-contextualized open metaverse standards.

Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2022.

Tris Pharma, Inc. (“Tris”), a fully integrated pharmaceutical company with a robust portfolio of CNS products announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its decision on July 7, 2022 upholding the validity and infringement of various patents relating to Quillivant XR ®.

ReGelTec, Inc., announced that Dr. Douglas Beall won the award for Best Abstract at the American Society for Pain and Neuroscience annual meeting that just concluded in Miami, FL.

Organicell Regenerative Medicine, Inc . announced today that it has secured $4.0 million in funding to finance clinical trials of its products and for general working capital purposes.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a pharmacokinetic study for AVT03 (denosumab), a biosimilar candidate to Prolia® and Xgeva®.

F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star”), operating through its subsidiary, F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives, today announced that it has entered into a license agreement with Takeda.